CJC-1295 with DAC is an investigational growth hormone-releasing hormone analog designed to stimulate growth hormone and IGF-1 for longer than short-acting GHRH peptides. Small human studies show hormone-level increases, but not proven anti-aging, fat-loss, recovery, sleep, muscle, or testosterone benefits. It is not FDA-approved, and long-term safety data are limited 1.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What is CJC-1295 with DAC?
CJC-1295 with DAC is an investigational peptide modeled after growth hormone-releasing hormone, or GHRH. In a small randomized human study, it was studied as a long-acting analog that increased growth hormone and insulin-like growth factor 1, or IGF-1, for days after a single injection 1.
What DAC means
DAC stands for Drug Affinity Complex. In simple terms, it is a chemical add-on that helps the peptide bind to albumin, a blood protein, so the signal lasts longer than a short-acting GHRH peptide 1.
How it differs from Modified GRF 1-29 or no DAC
CJC-1295 without DAC is often used online to mean Modified GRF 1-29, a shorter-acting GHRH analog. That naming can be confusing, so we recommend reading more carefully about CJC-1295 no DAC before assuming the two are interchangeable.
Why the naming is confusing
The phrase CJC-1295 may refer to the DAC version in published human studies, while wellness websites may use it loosely for no-DAC blends. That matters because duration of action, safety questions, and evidence are not the same across products 1.
How does CJC-1295 with DAC work in the body?
CJC-1295 with DAC works at the pituitary gland, where GHRH signaling tells the body to release growth hormone. The DAC design may extend that signal for days, but a longer hormone signal does not prove better health outcomes 1.
Growth hormone can increase IGF-1, a hormone involved in tissue growth, bone metabolism, and other body processes. But GH and IGF-1 are biomarkers. Higher marker levels do not automatically mean longer life, more muscle, better sleep, or safer recovery 1.
One clinical study reported that pulsatile growth hormone secretion persisted during continuous stimulation with CJC-1295, which is important because normal GH release is naturally pulsed rather than flat 2. Even so, this was still a hormone-pattern study, not a proof of patient benefit.
What does human research show about CJC-1295 with DAC?
The best human evidence for CJC-1295 with DAC is small and early. It shows changes in GH and IGF-1 over days, not proven clinical outcomes such as weight loss, muscle gain, injury recovery, sleep quality, or longevity 1.
The 2006 randomized healthy-adult study
Teichman and colleagues studied CJC-1295 in healthy adults and reported prolonged GH and IGF-1 stimulation after subcutaneous dosing 1. The key point for patients is what the trial measured: hormone response, not whether people lived longer, lost fat, gained muscle, or recovered faster.
The 2006 pulsatile GH secretion study
Ionescu and Frohman reported that pulsatile GH secretion persisted during continuous stimulation with CJC-1295 2. This supports a mechanism question, but it does not establish a treatment benefit in healthy adults.
The terminated HIV visceral obesity trial
A Phase 2 study registered CJC-1295 for HIV patients with visceral obesity, with an estimated enrollment of 120, but the trial was terminated 7. A terminated trial should not be used as proof that CJC-1295 improves visceral fat or body composition.
| Evidence source | Population | What it measured | What it does not prove |
|---|---|---|---|
| Teichman et al., 2006 | Healthy adults | GH and IGF-1 response after CJC-1295 | Longevity, fat loss, muscle gain, sleep, recovery, testosterone benefit |
| Ionescu and Frohman, 2006 | Small human clinical study | Whether GH pulses persisted during CJC-1295 stimulation | Long-term safety or clinical benefit |
| ClinicalTrials.gov NCT00267527 | HIV patients with visceral obesity | Planned Phase 2 clinical outcomes | The study was terminated, so it does not prove benefit |
| Recent sports medicine reviews | Peptide therapies broadly | Regulatory, safety, and evidence concerns | CJC-1295-specific clinical outcomes |
What is CJC-1295 with DAC good for?
The honest answer is narrow: CJC-1295 with DAC has been studied for changing GH and IGF-1 hormone markers. It has not been proven to improve anti-aging, longevity, fat loss, muscle gain, sleep, recovery, or testosterone in healthy adults 1.
Online claims often connect CJC-1295 to body recomposition, faster healing, deeper sleep, or healthy aging. Those claims may sound biologically plausible because GH and IGF-1 affect metabolism and tissue signaling, but plausibility is not the same as outcome data 3.
Longevity claims need extra caution. A hormone-marker change in a short study is not evidence that a peptide extends human lifespan or healthspan. Recent medical reviews describe many peptide therapies as emerging and emphasize uncertainty around safety, regulation, and clinical use 4.
What are the possible negative effects of CJC-1295?
CJC-1295 side effects are not fully known because long-term human safety data are limited. Short-term or plausible concerns include injection-site reactions, swelling or edema, headache, changes in glucose handling, and risks related to higher GH and IGF-1 signaling 1.
People with a cancer history, pituitary disorder, diabetes risk, insulin resistance, edema, untreated sleep apnea, or unclear hormone symptoms should be especially cautious. GH and IGF-1 pathways affect growth and metabolism, so a clinician may need to review medical history and lab context before any hormone-related peptide is considered 5.
For athletes, CJC-1295 also raises sport-rule concerns. Research on synthetic GHRH analog detection shows these compounds matter in drug-testing contexts, so athletes should verify current rules with their sport governing body before using any growth hormone secretagogue 6.
If you want a deeper safety review, our guide to CJC-1295 side effects explains common, serious, and long-term concerns in more detail.
Does CJC-1295 raise testosterone?
CJC-1295 is not a testosterone medication. Its main studied pathway is GHRH signaling, growth hormone, and IGF-1, not the hypothalamic-pituitary-gonadal axis that regulates testosterone 1.
Symptoms often blamed on low testosterone, such as low libido, fatigue, mood changes, or loss of strength, can have many causes. They deserve a separate medical evaluation rather than assuming a GH-related peptide is the right answer.
How is CJC-1295 with DAC different from sermorelin?
CJC-1295 with DAC and sermorelin both relate to GHRH signaling, but they are not the same peptide. CJC-1295 with DAC was designed for longer activity, while sermorelin is a shorter GHRH analog used in clinical discussions about GH-axis stimulation.
At Chia, we do not offer CJC-1295 with DAC or CJC-1295 without DAC. We do offer sermorelin in injection, nasal spray, and tablet forms, with injection plans currently starting at $179/month; treatment requires an online health questionnaire and licensed-provider review, and a prescription is not guaranteed.
| Question | CJC-1295 with DAC | Sermorelin |
|---|---|---|
| What is it? | Investigational long-acting GHRH analog | GHRH analog used in GH-axis care discussions |
| What is the evidence focus? | Small human studies measuring GH and IGF-1 markers | Clinical use depends on patient context and provider evaluation |
| Does Chia offer it? | No | Yes: injection, nasal spray, and tablets |
| Main patient question | What human outcomes and long-term safety data exist? | Is this appropriate for my goals, risks, labs, and history? |
If you are comparing GH-axis peptides, our article on sermorelin vs CJC-1295 no DAC is a useful next read. You can also review our broader CJC-1295 guide for naming and evidence basics.
Can you get CJC-1295 with DAC online?
CJC-1295 with DAC is not FDA-approved for any indication, and Chia does not offer it. Be careful with research-only peptide websites, because a product sold for laboratory research is not the same as a medication evaluated for human use.
FDA has warned that some bulk drug substances used in compounding may present significant safety risks, and FDA-reviewed safety, quality, and effectiveness cannot be assumed for unapproved peptide products 8. A research label, purity claim, or certificate of analysis does not replace clinician oversight.
The safer access question is not “Which website ships fastest?” It is “Is there a licensed clinician, a clear medical reason, appropriate monitoring, and a pharmacy pathway that follows the law?” Our guide to finding a legitimate peptide source walks through those questions.
What safer questions should patients ask before considering any growth-hormone peptide?
Before considering any growth hormone secretagogue, ask what diagnosis or goal is being addressed, what human evidence supports that goal, and what monitoring may be needed. A hormone-marker study alone is not enough to prove real-world benefit 4.
- What specific problem are we trying to address: diagnosed GH deficiency, body composition, fatigue, recovery, sleep, or something else?
- What human evidence supports this goal, and does it measure outcomes I care about or only hormone markers?
- What baseline labs, medical history, cancer screening history, glucose markers, or sleep apnea risks should be reviewed first?
- What side effects should make me stop and contact a clinician?
- Are there alternatives with clearer evidence, such as sleep treatment, resistance training, nutrition support, or an approved medication for a diagnosed condition?
- If I compete in sport, does my governing body prohibit this class of compound?
At Chia, we use this same cautious framework when evaluating hormone-adjacent therapies we do offer. For any online peptide care, the key safety line is licensed-provider review and a state-licensed 503A pharmacy pathway, not research-only purchasing.
CJC-1295 with DAC is designed to stimulate the pituitary gland through GHRH signaling, which can raise growth hormone and IGF-1 markers. Human evidence is limited to early studies of hormone response, not proven clinical benefits.
No. CJC-1295 with DAC is a longer-acting peptide designed to bind albumin. CJC-1295 no DAC usually refers to Modified GRF 1-29, a shorter-acting GHRH analog.
No. CJC-1295 with DAC is not FDA-approved for any indication, and Chia does not offer CJC-1295 with DAC or CJC-1295 without DAC.
Those claims are not proven in strong human outcome trials. Small studies show changes in growth hormone and IGF-1 markers, but marker changes do not prove muscle gain or fat loss.
Sleep and recovery claims are common online, but they are not established by strong human clinical outcome data for CJC-1295 with DAC.
CJC-1295 is not a testosterone medication. It is studied through the growth hormone and IGF-1 pathway, not as a direct testosterone therapy.
Possible concerns include injection-site reactions, swelling or edema, headache, glucose changes, and unknown long-term risks related to higher GH and IGF-1 signaling. People with cancer history, diabetes risk, pituitary disorders, edema, or sleep apnea should be especially cautious.
Athletes should verify current rules with their sport governing body before using any growth hormone secretagogue. This class can raise drug-testing and eligibility concerns.
References
- 1.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism. 2006.
- 2.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology and Metabolism. 2006.
- 3.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews. 2026.
- 4.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
- 5.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026.
- 6.Memdouh S, Gavrilović I, Ng K, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021.
- 7.ClinicalTrials.gov. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. NCT00267527. Terminated Phase 2 study. 2005.
- 8.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
